BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36602577)

  • 1. Investigating PSMA-PET/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance.
    Wong LM; Koschel S; Whish-Wilson T; Farag M; Bolton D; Zargar H; Corcoran N; Lawrentschuk N; Christov A; Thomas L; Perry E; Heinze S; Taubman K; Sutherland T
    World J Urol; 2023 Feb; 41(2):463-469. PubMed ID: 36602577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer.
    Tran V; Hong A; Sutherland T; Taubman K; Lee SF; Lenaghan D; Sethi K; Corcoran NM; Lawrentschuk N; Woo H; Tarlinton L; Bolton D; Spelman T; Thomas L; Booth R; Hegarty J; Perry E; Wong LM
    BMJ Open; 2022 Sep; 12(9):e061815. PubMed ID: 36123093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Donato P; Morton A; Yaxley J; Ranasinghe S; Teloken PE; Kyle S; Coughlin G; Esler R; Dunglison N; Gardiner RA; Roberts MJ
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1843-1851. PubMed ID: 31912257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Utility of
    Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
    Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX).
    Lopci E; Lazzeri M; Colombo P; Casale P; Buffi NM; Saita A; Peschechera R; Hurle R; Marzo K; Leonardi L; Morenghi E; Balzarini L; Disconzi L; Guazzoni G; Chiti A; Lughezzani G
    Urol Int; 2023; 107(5):433-439. PubMed ID: 36724746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer.
    Bagguley D; Harewood L; McKenzie D; Ptasznik G; Ong S; Chengodu T; Woon D; Sim K; Sheldon J; Lawrentschuk N
    BJU Int; 2024 Apr; 133 Suppl 4():27-36. PubMed ID: 37904302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer.
    Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L
    BJU Int; 2023 May; 131(5):588-595. PubMed ID: 36371669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of
    Ferraro DA; Becker AS; Kranzbühler B; Mebert I; Baltensperger A; Zeimpekis KG; Grünig H; Messerli M; Rupp NJ; Rueschoff JH; Mortezavi A; Donati OF; Sapienza MT; Eberli D; Burger IA
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3315-3324. PubMed ID: 33620559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection Rate of
    Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
    Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Evaluation of
    Gaur S; Mena E; Harmon SA; Lindenberg ML; Adler S; Ton AT; Shih JH; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Mease RC; Pomper MG; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer.
    Pepe P; Pepe L; Tamburo M; Marletta G; Pennisi M; Fraggetta F
    Arch Ital Urol Androl; 2022 Sep; 94(3):274-277. PubMed ID: 36165469
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Berger I; Annabattula C; Lewis J; Shetty DV; Kam J; Maclean F; Arianayagam M; Canagasingham B; Ferguson R; Khadra M; Ko R; Winter M; Loh H; Varol C
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):204-211. PubMed ID: 29858591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 68Ga-PSMA PET/CT evaluation in men enrolled in prostate cancer Active Surveillance.
    Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
    Arch Ital Urol Androl; 2023 May; 95(2):11322. PubMed ID: 37212907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [68Ga-PSMA-11 PET/mpMRI for local detection of primary prostate cancer in men with a negative prior biopsy].
    Maurer T; Gesterkamp H; Nguyen N; Westenfelder K; Gschwend JE; Budäus L; Rauscher I; Vag T; Weber W; Eiber M
    Aktuelle Urol; 2021 Apr; 52(2):143-148. PubMed ID: 32854128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Evaluation of
    Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
    Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.